Altimmune Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Altimmune, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue0.020.43-0.074.418.195.80
Cost of Revenue82.2365.8070.4573.8433.510.00
Gross Profit-82.21-65.37-0.07-69.438.195.80
Operating Expenses
Research & Development82.2365.8070.5474.5449.7717.77
Selling, General & Administrative20.9718.1417.1315.4113.218.50
Operating Expenses20.9718.1487.6715.4162.98-27.27
Operating Income-103.17-83.51-87.74-84.84-54.80-20.46
Other Income/Expense
Interest Income8.077.352.870.200.320.00
Interest Expense-0.01-0.040.010.00-0.010.00
Other Income/Expense0.050.17-0.03-0.37-0.02-0.02
Income
Income Before Tax-95.06-88.45-84.91-97.09-54.46-20.58
Income Tax Expense0.000.00-0.200.00-5.42-0.06
Net Income-95.06-88.45-84.71-97.09-49.04-20.52
Net Income - Continuous Operations-95.06-88.45-84.71-97.090.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.00
EBITDA-102.93-83.03-84.41-84.29-54.02-20.19
EBIT-103.17-83.51-84.90-84.84-54.45-20.58
Depreciation & Amortization0.240.480.490.550.30-0.24
Earnings Per Share
Basic EPS-1.00-2.00-2.00-2.00-2.00-
Diluted EPS-1.00-2.00-2.00-2.00-2.00-2.00
Basic Shares Outstanding71.0053.2546.9341.2825.6413.12
Diluted Shares Outstanding71.0053.2546.9341.2825.6412.83